Biocryst Pharmaceuticals Inc $13.70

down 0.00


26/8/2014 05:15 PM  |  NASDAQ : BCRX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get BCRX Trend Analysis - it has outperformed the S&P 500 by 80%

Partner Headlines

  1. Biotechs That Might Benefit From Ebola

    Benzinga
  2. Benzinga's Top #PreMarket Gainers

    Benzinga
  3. Stocks Hitting 52-Week Highs

    Benzinga
  4. Benzinga's Top Initiations

    Benzinga
  5. JP Morgan Initiates BioCryst Pharmaceuticals At Overweight

    Benzinga
  6. MLV & Co Sees Positive Momentum Going Into 2H14 For BioCryst Pharmaceuticals

    Benzinga
  7. Ebola Stocks Continue Higher

    Benzinga
  8. UPDATE: Wells Fargo Upgrades BioCryst

    Benzinga
  9. UPDATE: H.C. Wainwright & Co. Initiates Coverage on BioCryst Pharmaceuticals ...

    Benzinga
  10. Benzinga's Top Initiations

    Benzinga
  11. Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, ...

    Benzinga
  12. Benzinga's Top #PreMarket Gainers

    Benzinga
  13. Benzinga's Top Downgrades

    Benzinga
  14. Benzinga's Top Initiations

    Benzinga
  15. UPDATE: JMP Securities Places BioCryst Pharmaceuticals PT Under Review, ...

    Benzinga
  16. US Stock Futures Gain Ahead Of GDP Data

    Benzinga
  17. BioCryst Files Peramivir NDA for Influenza

    Benzinga
  18. Benzinga's Top #PreMarket Gainers

    Benzinga
  19. BioCryst Selects Two Plasma Kallikrein Inhibitors for Hereditary Angioedema ...

    Benzinga
  20. BioCryst Initiates Phase 2a Clinical Trial of BCX4161 in Patients with ...

    Benzinga
  21. Benzinga's Top Pre-Market Gainers

    Benzinga
  22. BioCryst Awarded Up to $22M Contract by the NIAID to Develop BCX4430 for ...

    Benzinga
  23. JMP Calls BioCryst's Oral Kallikrein 'Potential Game Changer,' Believes ...

    Benzinga
  24. UPDATE: JMP Securities Raises PT on BioCryst Pharmaceuticals on Potential ...

    Benzinga
  25. Benzinga's Top Pre-Market Gainers

    Benzinga
  26. FDA Removes Clinical Hold on BioCryst's BCX 4161 -8K

    Benzinga
  27. Benzinga's Top Pre-Market Gainers

    Benzinga
  28. BioCryst Prices 4M Share Offering at $4.40/Share

    Benzinga
  29. UPDATE: Bank of America Downgrades BioCryst Pharmaceuticals on Valuation

    Benzinga
  30. Benzinga's Top Pre-Market Losers

    Benzinga
  31. UPDATE: Bank of America Resumes Coverage on BioCryst Pharmaceuticals with ...

    Benzinga
  32. Benzinga's Small Cap Movers for Wednesday January 2, 2013

    Benzinga
  33. Ballots Are In: Worst CEO in the Biotech Industry Is . . .

    YCharts
  34. BioCryst Pharmaceuticals, Presidio Pharmaceuticals Terminate Merger Agreement

    Benzinga
  35. BioCryst Broad-Spectrum Antiviral BCX4430 Shows Effective and Well Tolerated ...

    Benzinga
  36. BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  37. BioCryst Announces Withdrawal of BCX5191 Investigational New Drug Application ...

    Benzinga
  38. Benzinga's M&A Chatter for Thursday October 18, 2012

    Benzinga
  39. BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge

    Benzinga
  40. BioCryst Pharmaceuticals, Presidio Pharmaceuticals to Merge

    Benzinga
  41. BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  42. A Peek Into The Market Before The Trading Starts

    Benzinga
  43. IHS, Ebix Included in Stocks Up on High Volume Friday

    FoxBusiness
  44. Swine Flu Has BioPharma as Happy as Pigs in Filth

    Benzinga
  45. Swine Flu Has BioPharma as Happy as Pigs in Filth

    Benzinga
  46. Swine Flu Outbreak in Mexico Sends Small BioPharma Sky-High

    Benzinga
  47. Benzinga's Microcap Movers for Thursday January 12, 2012

    Benzinga
  48. Oink Oink: Profit From The Return Of Swine Flu

    Benzinga
  49. UPDATE: Bank of America Meets with BioCryst Pharma Management on BCX42 ...

    Benzinga
  50. Bank of America Comments on BCRX Phase-3 Data

    Benzinga
Trading Center